VHAQ vs. ENTA, XBIT, IMMP, EBS, ME, DSGN, ACRV, FHTX, ALDX, and TSVT
Should you be buying Viveon Health Acquisition stock or one of its competitors? The main competitors of Viveon Health Acquisition include Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), Emergent BioSolutions (EBS), 23andMe (ME), Design Therapeutics (DSGN), Acrivon Therapeutics (ACRV), Foghorn Therapeutics (FHTX), Aldeyra Therapeutics (ALDX), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical preparations" industry.
Viveon Health Acquisition (NYSE:VHAQ) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends.
Viveon Health Acquisition has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.
Enanta Pharmaceuticals received 310 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users.
In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 2 mentions for Enanta Pharmaceuticals and 0 mentions for Viveon Health Acquisition. Enanta Pharmaceuticals' average media sentiment score of 1.25 beat Viveon Health Acquisition's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
Enanta Pharmaceuticals has a consensus price target of $19.00, indicating a potential upside of 52.37%. Given Enanta Pharmaceuticals' higher probable upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Viveon Health Acquisition.
22.1% of Viveon Health Acquisition shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 75.3% of Viveon Health Acquisition shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Viveon Health Acquisition has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -180.76%. Viveon Health Acquisition's return on equity of 0.00% beat Enanta Pharmaceuticals' return on equity.
Viveon Health Acquisition has higher earnings, but lower revenue than Enanta Pharmaceuticals.
Summary
Enanta Pharmaceuticals beats Viveon Health Acquisition on 8 of the 13 factors compared between the two stocks.
Get Viveon Health Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for VHAQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VHAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viveon Health Acquisition Competitors List
Related Companies and Tools
